LeadArtis participates in the third Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting

09-12-2016

The third IACT review meeting took place on October 25-26, 2016 in Frankfurt, Germany. LeadArtis is a partner in the Immunostimulatory Agonist Antibodies for Cancer Therapy effort, a 6.9M€ funding initiative which incorporates long-standing expertise in agonist immunostimulatory antibodies (IS-Abs) from research institutions and small-medium enterprises (SEM) in five European countries (Germany, Italy, Spain, Sweden and United Kingdom). The IACT program aims to translate the agonist IS-Ab concept into immune oncology treatments (http://www.iact-project.eu/). Two ongoing clinical trials are pivotal to bring forward the pre-clinical Proof of Concept. Analogous SME-driven effort aims at the development of 2nd generation agonist IS-Abs with superior therapeutic index. LeadArtis is applying its TrimerbodyTM technology for the generation of novel immune stimulating multivalent antibodies.

Latest News

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...

LeadArtis participates in the third Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting
09-12-2016

The third IACT review meeting took place on October 25-26, 2016 in Frankfurt, Germany. LeadArtis...

Leadartis to present at BioSpain 2016 in Bilbao
25-08-2016

Leadartis will participate in BioSpain 2016 to be held...